REBEKAH GARRARD: Open Payments
NPI 1952656027 · LAFAYETTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$35,472 in 226 payments from 36 companies in 2025. Trend: 2023 $12,283 · 2024 $28,922 · 2025 $35,472
Consulting: $15,630Speaker / faculty: $8,592Food & beverage: $6,576Travel & lodging: $4,560Education: $114
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 29 | $10,549 |
| Janssen Scientific Affairs, LLC | 12 | $8,664 |
| Novartis Pharmaceuticals Corporation | 29 | $6,038 |
| E.R. Squibb & Sons, L.L.C. | 12 | $5,789 |
| Amgen Inc. | 34 | $1,062 |
| ABBVIE INC. | 17 | $525 |
| GENZYME CORPORATION | 8 | $448 |
| Alexion Pharmaceuticals, Inc. | 2 | $443 |
| UCB, Inc. | 10 | $208 |
| BETA BIONICS, INC. | 7 | $187 |
Products named: TREMFYA, COSENTYX, KRYSTEXXA, KEVZARA, STRENSIQ, SKYRIZI, OTEZLA, Bimzelx.
Industry payments across LA — which companies pay providers there.
